Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Is Breast Involvement in Marginal Zone Lymphoma Associated with Worse Outcomes? a Nationwide Analysis

Mohammad M Alhousani, Kiley Felton, Kathleen Faringer, Cyrus Khan, John Lister, Yazan Samhouri

Blood (2023) 142 (Supplement 1): 6157.

https://doi.org/10.1182/blood-2023-188039

Published: 2023

Journal Articles

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Nathan Roberts, John Lister, N. Nora Bennani, Salvia Jain, Tammy Battaglia, Emily C. Ayers, Craig A. Portell, Michael E. Williams, Prem Batchala, Ipsita Pal, Owen A. O'Connor, John Sanil Manavalan, Enrica Marchi

Blood (2022) 140 (Supplement 1): 9425–9426.

https://doi.org/10.1182/blood-2022-170181

Published: 2022

Journal Articles

A Case of Primary Dural Lymphoma Treated with Bendamustine and Rituxan

Sushanth Sreenivasan, Shivani Shah, Risha Solanki, Pragnan Kancharla, John Lister, Cyrus Khan, Yazan Samhouri

Blood (2022) 140 (Supplement 1): 11995–11996.

https://doi.org/10.1182/blood-2022-168162

Published: 2022

Journal Articles

Intrathecal Chemotherapy As a Potential Alternative Treatment for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome

Urwat Til Vusqa, Palash Asawa, Maitreyee Rai, Yazan Samhouri, Prerna Mewawalla, Anna Koget, Santhosh Sadashiv, Cyrus Kahn, Salman Fazal, John Lister

Blood (2021) 138 (Supplement 1): 4816.

https://doi.org/10.1182/blood-2021-151113

Published: 2021

Journal Articles

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Javier Pinilla Ibarz, Meixiao Long, John Lister, Jennifer A. Woyach, Friedrich Graf Finckenstein, Madan Jagasia, Selda Samakoglu, Bhagyashree Yadav, Huiling Li, John C. Byrd

Blood (2021) 138 (Supplement 1): 3846.

https://doi.org/10.1182/blood-2021-145775

Published: 2021

Journal Articles

The Role of Checkpoint Inhibitors in Adults with Classical Hodgkin Lymphoma; A Systematic Review and Meta-Analysis of Phase II and III Clinical Trials

Yazan Samhouri, MD, Muhammad Yasir Anwar, Ali Younas Khan, MD, Urwat Til Vusqa, MD, Iqraa Ansar, MDMBBS, Muhammad S. Anil, MD, Lynna Alnimer, MD, Taha Sheikh, MDMPH, Muhammad Aslam Khan, MD, Faiz Anwer, MD, Salman Fazal, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-140591

Published: 2020

Journal Articles

Hematological Complications of Donor Origin Following Allogeneic Hematopoietic Stem Cell Transplantation

Ahmed Khattab, MD, Sunita Patruni, MD, Gina Berteotti, Thejus Jayakrishnan, MBBS, Salman Fazal, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-140084

Published: 2020

Journal Articles

Selection of Treatment and Survival in Patients with Gray Zone Lymphoma; A Comprehensive Population-Based Analysis

Yazan Samhouri, MD, Thejus Jayakrishnan, MBBS, Lynna Alnimer, MD, Deanna Huffman, DO, Veli Bakalov, MD, Rodney E Wegner, MD, Salman Fazal, MD, Cyrus Kahn, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137317

Published: 2020

Journal Articles

Patterns of Treatment and Survival in Elderly Patients with Primary CNS Lymphoma; An 11-Year Population-Based Analysis

Yazan Samhouri, MD, Moaath Mustafa Ali, MD MPH, Thejus Jayakrishnan, MBBS, Chelsea Peterson, DO, Veli Bakalov, MD, Salman Fazal, MD, Cyrus Kahn, MD, Rodney E Wegner, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137300

Published: 2020

Journal Articles

Predictors and Long Term Outcomes for DLBCL Patients Undergoing Surgery Prior to Systemic Therapy

Thejus Jayakrishnan, MBBS, Yazan Samhouri, MD, Veli Bakalov, MD, Zena Chahine, MD, Rodney E Wegner, MD, Cyrus Khan, MD, Salman Fazal, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-137827

Published: 2020

Journal Articles

Autologous Stem Cell Transplantation in Multiple Myeloma Patients Older Than 65 Year-Old, 12-Years Analysis of National Cancer Database

Veli Bakalov, MD, Amulya Yellala, MD, Raed Benkhadra, MD, Thejus Jayakrishnan, MD, Yazan Samhouri, MD, John Lister, MD, Santhosh Sadashiv, MD, Rodney E Wegner, MD

Blood (2019) 134 (Supplement_1): 2195.

https://doi.org/10.1182/blood-2019-127879

Published: 2019

Journal Articles

In-Hospital Complications and Outcomes of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Older Than 65-Years Old in the United States: National Inpatient Sample Analysis, 2011-2015

Veli Bakalov, MD, Amy Tang, PhD, Hira G. Shaikh, MD, Shrunjal Shah, MD, Zena Chahine, MD, Robert B. Kaplan, MDBS,BA, John Lister, MD, Santhosh Sadashiv, MD

Blood (2019) 134 (Supplement_1): 4764.

https://doi.org/10.1182/blood-2019-131472

Published: 2019

Journal Articles

The Risk Factors of the Venous Thromboembolism in Hospitalized Patients with Hematologic Malignancies in the United States: National Inpatient Sample Analysis, 2011-2015

Veli Bakalov, MD, Amy Tang, PhD, Amulya Yellala, MD, Robert B. Kaplan, MDBS, BA, John Lister, MD, Santhosh Sadashiv, MD

Blood (2018) 132 (Supplement 1): 2310.

https://doi.org/10.1182/blood-2018-99-115282

Published: 2018

Journal Articles

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubucin and Rituximab (da-EPOCH-R) Vs Rituxan, Cyclophosphamide, Doxorubucin, Vincristine and Prednisone (R-CHOP) As First Line Treatment for Diffuse Large B-Cell Lymphoma (DLBCL)

Parikshit Padhi, MD, Abhishek Chilkulwar, MD, Cyrus Khan, MD, Monank Patel, PharmD, BCOP, John Lister, MD, Xiaoqin Tang, PhD Director of Biostatistics

Blood (2016) 128 (22): 5410.

https://doi.org/10.1182/blood.V128.22.5410.5410

Published: 2016

Journal Articles

Serum Free Light Chain Concentration (>1000mg/dl) at Diagnosis and at Relapse Predicts for Very Poor Prognosis in Multiple Myeloma

Abhishek Chilkulwar, MD, Prerna Mewawalla, MD, Anna Miller, Gina Berteotti, Entezam Sahovic, MD, John Lister, MD

Blood (2016) 128 (22): 5698.

https://doi.org/10.1182/blood.V128.22.5698.5698

Published: 2016

Journal Articles

Induction Therapy with Dasatinib and Prednisone for Patients with Philadelphia Positive ALL

Abhishek Chilkulwar, MD, Salman Fazal, MD, Jocelyn T. De Yao, MD, Parik Padhi, MD, Cyrus Khan, MD, John Lister, MD

Blood (2015) 126 (23): 4907.

https://doi.org/10.1182/blood.V126.23.4907.4907

Published: 2015

Journal Articles

Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo ® (vinCRIStine sulfate LIPOSOME injection)

Olivia R. Deitcher, Stuart L. Goldberg, MD, Wendy Stock, MD, Gary J. Schiller, MD, John Lister, MD, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD, Susan O'Brien, M.D.

Blood (2012) 120 (21): 4805.

https://doi.org/10.1182/blood.V120.21.4805.4805

Published: 2012

Journal Articles

Vincristine Sulfate Liposomes Injection (Marqibo ® ) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Gary J. Schiller, MD, John Lister, MD, Leonard T. Heffner, MD, Stuart L. Goldberg, MD, Lloyd E. Damon, MD, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD

Blood (2011) 118 (21): 4235.

https://doi.org/10.1182/blood.V118.21.4235.4235

Published: 2011

Journal Articles

Neurological Toxicity Profile of Weekly Vincristine Sulfate Liposomes Injection (Marqibo ® ) 2.25 mg/m 2 Compared to Historical Standard Vincristine Sulfate 1.4 mg/m 2 , 2 mg, and 4 mg Administered Less Frequently

Lloyd E. Damon, MD, Stuart L. Goldberg, MD, Leonard T. Heffner, MD, John Lister, MD, Gary J. Schiller, MD, Steven R. Deitcher, MD

Blood (2011) 118 (21): 4247.

https://doi.org/10.1182/blood.V118.21.4247.4247

Published: 2011

Journal Articles

Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Stuart L Goldberg, MD, Pierre Fenaux, MD, PhD, Michael D Craig, MD, Emmanuel Gyan, MD, PhD, John Lister, MD, Jeannine Kassis, MD, Arnaud Pigneux, MD, PhD, Gary J Schiller, MD, JungAh Jung, PhD, E. Jane Leonard, MSc, Howard Fingert, MD, Peter Westervelt, MD, PhD

Blood (2010) 116 (21): 3273.

https://doi.org/10.1182/blood.V116.21.3273.3273

Published: 2010

NARROW

Is Breast Involvement in Marginal Zone Lymphoma Associated with Worse Outcomes? a Nationwide Analysis

Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

A Case of Primary Dural Lymphoma Treated with Bendamustine and Rituxan

Intrathecal Chemotherapy As a Potential Alternative Treatment for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

The Role of Checkpoint Inhibitors in Adults with Classical Hodgkin Lymphoma; A Systematic Review and Meta-Analysis of Phase II and III Clinical Trials

Hematological Complications of Donor Origin Following Allogeneic Hematopoietic Stem Cell Transplantation

Selection of Treatment and Survival in Patients with Gray Zone Lymphoma; A Comprehensive Population-Based Analysis

Patterns of Treatment and Survival in Elderly Patients with Primary CNS Lymphoma; An 11-Year Population-Based Analysis

Predictors and Long Term Outcomes for DLBCL Patients Undergoing Surgery Prior to Systemic Therapy

Autologous Stem Cell Transplantation in Multiple Myeloma Patients Older Than 65 Year-Old, 12-Years Analysis of National Cancer Database

In-Hospital Complications and Outcomes of Autologous Stem Cell Transplantation in Multiple Myeloma Patients Older Than 65-Years Old in the United States: National Inpatient Sample Analysis, 2011-2015

The Risk Factors of the Venous Thromboembolism in Hospitalized Patients with Hematologic Malignancies in the United States: National Inpatient Sample Analysis, 2011-2015

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubucin and Rituximab (da-EPOCH-R) Vs Rituxan, Cyclophosphamide, Doxorubucin, Vincristine and Prednisone (R-CHOP) As First Line Treatment for Diffuse Large B-Cell Lymphoma (DLBCL)

Serum Free Light Chain Concentration (>1000mg/dl) at Diagnosis and at Relapse Predicts for Very Poor Prognosis in Multiple Myeloma

Induction Therapy with Dasatinib and Prednisone for Patients with Philadelphia Positive ALL

Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo ® (vinCRIStine sulfate LIPOSOME injection)

Vincristine Sulfate Liposomes Injection (Marqibo ® ) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Neurological Toxicity Profile of Weekly Vincristine Sulfate Liposomes Injection (Marqibo ® ) 2.25 mg/m 2 Compared to Historical Standard Vincristine Sulfate 1.4 mg/m 2 , 2 mg, and 4 mg Administered Less Frequently

Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only